(12) **Translation of european patent specification**

(11) **NO/EP 2200431 B1**

NORWAY

(19) NO
(51) Int Cl.
A61K 31/505 (2006.01)
A61K 31/55 (2006.01)
A61K 38/17 (2006.01)
A61P 35/00 (2006.01)

Norwegian Industrial Property Office

(21)	Translation Published	2016.10.10
(80)	Date of The European Patent Office Publication of the Granted Patent	2016.07.20
(86)	European Application Nr.	08830633.7
(86)	European Filing Date	2008.09.10
(87)	The European Application's Publication Date	2010.06.30
(30)	Priority	2007.09.10, US, 971144 P 2007.12.13, US, 13372
(84)	Designated Contracting States:	AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR
(73)	Proprietor	Boston Biomedical, Inc., 640 Memorial Drive, Cambridge, MA 02139, US-USA
(72)	Inventor	LI, Chiang, Jia, Unit 16068 Museum Way, Cambridge, MA 02141, US-USA MIKULE, Keith, c/o Boston Biomedical, Inc.640 Memorial Drive, CambridgeMA 02139, US-USA LI, Youzhi, 37 Woodridge Road, WestwoodMA 02090, US-USA
(74)	Agent or Attorney	Orsnes Patent ApS, Forskerparken 10, DK-5230 ODENSE, Danmark

(54) Title **NOVEL COMPOSITIONS AND METHODS FOR CANCER TREATMENT**

(56) References Cited:
WO-A1-2005/058829
WO-A2-00/44774
WO-A2-2004/026253
WO-A2-2005/033048
WO-A2-2005/110477
WO-A2-2006/056399
WO-A2-2006/113790
WO-A2-2007/100640
WO-A2-2007/115269
WO-A2-2008/077062
WO-A2-2008/094321
US-A1- 2004 138 189
US-A1- 2006 247 318
SUN X ET AL: "Comparison of effects of the tyrosine kinase inhibitors AG957, AG490, and STI571 on BCR-ABL-expressing cells, demonstrating synergy between AG490 and STI571", BLOOD, vol. 97, no. 7, 1 January 2001 (2001-01-01), pages 2008-2015, XP001151676, AMERICAN SOCIETY OF HEMATOLOGY, US ISSN: 0006-4971, DOI: 10.1182/BLOOD.V97.7.2008
KIM KWANG WOON ET AL: "Inhibition of signal transducer and activator of transcription 3 activity results in down-regulation of Survivin following irradiation", MOLECULAR CANCER THERAPEUTICS, vol. 5, no. 11, November 2006 (2006-11), pages 2659-2665, XP002661520,

ISSN: 1535-7163
JOHNSON FAYE M ET AL: "Abrogation of signal transducer and activator of transcription 3 reactivation after Src kinase inhibition results in synergistic antitumor effects.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, vol. 13, no. 14, 15 July 2007 (2007-07-15) , pages 4233-4244, XP002661521, ISSN: 1078-0432
YAO ET AL.: "Experimental study on the growth inhibition of bladder cancer cells by signal conduction blocker AG490", JOURNAL OF CLINICAL UROLOGY, vol. 21, no. 5, May 2006 (2006-05), pages 379-382, XP002661522,
Colman et al.: "Effect of a small molecule inhibitor of the JAK2/STAT3 pathway on self-renewal of glioblastoma stem cells", Journal of Clinical Oncology, vol. 26, no. 15S May 2008 (2008-05), XP002661523, Retrieved from the Internet: URL:http://meeting.ascopubs.org/cgi/conten t/abstract/26/15_suppl/2003?sid=22d20bba-d 0ca-4739-a434-779df098ec93 [retrieved on 2010-10-17]
KATOH MASUKO ET AL: "STAT3-induced WNT5A signaling loop in embryonic stem cells, adult normal tissues, chronic persistent inflammation, rheumatoid arthritis and cancer (Review)", INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, vol. 19, no. 2, 1 February 2007 (2007-02-01), pages 273-278, XP009090900, SPANDIDOS PUBLICATIONS, GR ISSN: 1107-3756
YAU CINDY Y F ET AL: "Inhibition of integrin-linked kinase by QLT0254 inhibits Akt-dependent pathways and is growth inhibitory in orthotopic primary pancreatic cancer xenografts", CANCER RESEARCH, vol. 65, no. 4, 15 February 2005 (2005-02-15), pages 1497-1504, XP002661524, ISSN: 0008-5472
FRANK DAVID A: "STAT3 as a central mediator of neoplastic cellular transformation", CANCER LETTERS, vol. 251, no. 2, June 2007 (2007-06), pages 199-210, XP022059608, ISSN: 0304-3835
ZHOU JIANGBING ET AL: "Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 104, no. 41, October 2007 (2007-10), pages 16158-16163, XP002661526, ISSN: 0027-8424 -& ZHOU JIANGBING ET AL: "Corrections: Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 104, no. 49, 4 December 2007 (2007-12-04), XP002662722,
DATABASE CA [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; CHEN, CHENG CHANG ET AL: "Constituents of Markhamia hildebrandtii (Baker) Sprague and their antitumor activity", XP002661423, retrieved from STN Database accession no. 1986:568912
DESMOND JULIAN C ET AL: "The synthetic furanonaphthoquinone induces growth arrest, apoptosis and differentiation in a variety of leukaemias and multiple myeloma cells", BRITISH JOURNAL OF HAEMATOLOGY, vol. 131, no. 4, November 2005 (2005-11), pages 520-529, XP002661429, ISSN: 0007-1048
HIRAI KEI-ICHI ET AL: "Furanonaphthoquinone analogs possessing preferential antitumor activity compared to normal cells", CANCER DETECTION AND PREVENTION, ELSEVIER SCIENCE, vol. 223, no. 6, 1 January 1999 (1999-01-01), pages 539-550, XP009152976, ISSN: 0361-090X
MARY RIEBER: 'Mcl-1 cleavage and sustained phosphorylation of c-Jun-N-terminal kinase mediate melanoma apoptosis induced by 2-acetyl furanonaphthoquinone: roles of Bcl-2 and p53.' CANCER BIOLOGY & THERAPY vol. 7, no. 8, 01 August 2008, pages 1206 - 1211, XP055078281 ISSN: 1538-4047

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (http://worldwide.espacenet.com) or via the search engine on our website here: https://search.patentstyret.no/

PATENTKRAV

1. Kombinasjon omfattende et første middel for å hemme avvikende Stat3-reaksjonsveiaktivitet og et andre middel for anvendelse i å behandle et individ med en kreft som er forbundet med avvikende Stat3-reaksjonsveiaktivitet, hvori det første midlet velges fra gruppen som består av 2-(1-hydroksyetyl)-nafto[2,3-b]furan-4,9-dion, 2-acetyl-7-klor-nafto[2,3-b]furan-4,9-dion, 2-acetyl-7-fluor-nafto[2,3-b]furan-4,9-dion, 2-acetylnafto[2,3-b]furan-4,9-dion, 2-etyl-nafto[2,3-b]furan-4,9-dion og et farmasøytisk akseptabelt salt eller solvat derav; og det andre midlet velges fra gruppen som består av paklitaksel, erlotinib, sunitinib, lapatinib, sorafenib, karboplatin, doksorubicin, docetaksel, gemcitabin og etoposid.

2. Kombinasjonen ifølge krav 1 hvori kreften velges fra gruppen som består av brystkreft, hode- og halskreft, lungekreft, eggstokkreft, bukspyttkjertelkreft, kolorektalt karsinom, prostatakreft, nyrecellekarsinom, melanom, hepatocellulært karsinom, livmorhalskreft, sarkom, hjernesvulst, magekreft, multippelt myelom, leukemi og lymfom.

3. Kombinasjonen ifølge krav 1, hvori det første midlet er 2-acetylnafto[2,3-b]furan-4,9-dion eller et farmasøytisk akseptabelt salt eller solvat derav.

4. Kombinasjonen ifølge krav 1 eller krav 3 hvori kreften er metastatisk, refraktær overfor en standard første linjes kreftbehandling eller har gjenoppblusset.

5. Kombinasjonen ifølge krav 1, hvori det første midlet er 2-acetylnafto[2,3-b]furan-4,9-dion og det andre midlet er gemcitabin, hvori det første midlet formuleres i en sammensetning omfattende Gelucire®.